Nachar V - Search Results

1

Adding venetoclax to lenalidomide and rituximab is safe and effective in patients with untreated mantle cell lymphoma.

Phillips TJ, Bond D, Takiar R, Kump K, Kandarpa M, Boonstra P, Mayer TL, Nachar V, Wilcox RA, Carty SA, Karimi YH, Nikolovska-Coleska Z, Kaminski MS, Herrera AF, Maddocks K, Popplewell L, Danilov AV. Phillips TJ, et al. Among authors: nachar v. Blood Adv. 2023 Aug 22;7(16):4518-4527. doi: 10.1182/bloodadvances.2023009992. Blood Adv. 2023. PMID: 37013954 Free PMC article.

2

Dosing Vincristine in Dose-Adjusted EPOCH-R: To Cap or Not to Cap?

Weis TM, Perissinotti AJ, Nachar VR, Brown AM, Phillips TJ, Marini BL. Weis TM, et al. J Clin Oncol. 2019 Nov 1;37(31):2952. doi: 10.1200/JCO.19.01259. Epub 2019 Sep 18. J Clin Oncol. 2019. PMID: 31532723 No abstract available.

3

Impact of a vincristine dose cap on the incidence of neuropathies with DA-EPOCH-R for the treatment of aggressive lymphomas.

Weis TM, Marini BL, Nachar VR, Brown AM, Phillips TJ, Brown J, Wilcox RA, Kaminski MS, Devata S, Perissinotti AJ. Weis TM, et al. Leuk Lymphoma. 2020 May;61(5):1126-1132. doi: 10.1080/10428194.2019.1703969. Epub 2019 Dec 26. Leuk Lymphoma. 2020. PMID: 31876206

4

Evaluating the Role of Novel Oncology Agents: Oncology Stewardship in Relapsed/Refractory Diffuse Large B-Cell Lymphoma.

Bazzell BG, Benitez LL, Marini BL, Perissinotti AJ, Phillips TJ, Nachar VR. Bazzell BG, et al. Clin Lymphoma Myeloma Leuk. 2021 May;21(5):295-308. doi: 10.1016/j.clml.2020.12.018. Epub 2020 Dec 23. Clin Lymphoma Myeloma Leuk. 2021. PMID: 33485834 Review.

5

Late-onset complications with bendamustine versus CHOP or CVP based chemoimmunotherapy in indolent Non-Hodgkin's lymphoma.

Baek GT, Mathis NJ, Perissinotti AJ, Marini BL, Brown A, Phillips TJ, Wilcox RA, Nachar VR. Baek GT, et al. Among authors: nachar vr. Leuk Lymphoma. 2021 Dec;62(13):3138-3146. doi: 10.1080/10428194.2021.1953014. Epub 2021 Jul 15. Leuk Lymphoma. 2021. PMID: 34263702

6

[No title available]

[No authors listed] [No authors listed] PMID: 36164079

7

COVID-19 infection outcomes in patients receiving CD20 targeting T-cell engaging bispecific antibodies for B-cell non-Hodgkin lymphoma.

Nachar VR, Perissinotti AJ, Marini BL, Karimi YH, Phillips TJ. Nachar VR, et al. Ann Hematol. 2023 Sep;102(9):2635-2637. doi: 10.1007/s00277-023-05315-1. Epub 2023 Jun 9. Ann Hematol. 2023. PMID: 37294440 Free PMC article. No abstract available.

8

Incidence and risk factors for bacterial infection using bortezomib, lenalidomide, and dexamethasone (RVd) in newly diagnosed multiple myeloma.

Bici A, Pianko MJ, Nachar VR. Bici A, et al. Among authors: nachar vr. Leuk Lymphoma. 2023 Feb;64(2):407-414. doi: 10.1080/10428194.2022.2138380. Epub 2022 Oct 29. Leuk Lymphoma. 2023. PMID: 36308285 Free PMC article.

9

Successful rechallenge of rituximab following severe rituximab-induced acute thrombocytopenia in a patient with splenic marginal zone lymphoma.

Robinson AC, Nachar VR. Robinson AC, et al. J Oncol Pharm Pract. 2020 Jul;26(5):1248-1253. doi: 10.1177/1078155219890023. Epub 2019 Nov 25. J Oncol Pharm Pract. 2020. PMID: 31766968

10

Optimal sequence of daratumumab and elotuzumab in relapsed and refractory multiple myeloma.

Hoylman E, Brown A, Perissinotti AJ, Marini BL, Pianko M, Ye JC, Campagnaro E, Nachar VR. Hoylman E, et al. Leuk Lymphoma. 2020 Mar;61(3):691-698. doi: 10.1080/10428194.2019.1688324. Epub 2019 Nov 18. Leuk Lymphoma. 2020. PMID: 31739729

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

27 results

Search Page

Filters